Which Heart Tests Come First in a Cardiovascular Toxicology Evaluation and What They Show

The appointment letter says ‘echo, ECG, bloods’ in the same paragraph as the chemotherapy start date, and the woman holding it has never had so much as a murmur. She is 58, walks the dog twice a day, and her first thought is that someone has found a second problem she was not told about. Nobody has. What she is looking at is the ordinary front end of cardio oncology heart tests, the checks that happen before a treatment known to lean on the heart.

The confusion is understandable. Oncology and cardiology sound like separate buildings, and for a long time they were. Now they share a corridor, and the traffic in that corridor is mostly people who feel perfectly well.

This article walks through which tests come first in a cardiovascular toxicology evaluation, what each one can and cannot show, who tends to be tested early and who waits, and which signs should prompt a phone call rather than a wait for the next scheduled scan.

What is cardio-oncology, and why does a heart team get involved before cancer treatment?

Cardio-oncology is the branch of medicine that looks after the heart and blood vessels of people who have cancer, before, during and after treatment. It exists because the two fields collided in the clinic long before they met in the textbooks. Oncologists noticed that some patients who did well against their cancer later developed weak heart muscle, rhythm problems or high blood pressure, and cardiologists noticed that some of their heart failure patients shared a history of particular cancer drugs or chest radiation.

The heart team gets involved early for a simple reason: a baseline is only useful if it is taken before the exposure. Once treatment begins, no one can go back and measure what the heart looked like on day zero. That is why a cardio-oncology referral often lands in the same week as the treatment plan, sometimes to the surprise of a patient who has never had a heart complaint.

A referral is not a verdict. In most cases it means the proposed regimen belongs to a class with a recognized heart signal, or that the person already carries risk factors such as high blood pressure, diabetes, prior heart disease or older age. The evaluation is a risk assessment, not a diagnosis of heart disease.

What the field adds, beyond tests, is a shared conversation. The oncologist wants the most effective cancer plan; the cardiologist wants a heart that can carry it. When the two speak the same language, the answer is rarely ‘stop the cancer drug’ and far more often ‘monitor, protect and adjust if the numbers move.’ The tests described here are the vocabulary of that conversation, and understanding them makes the conversation easier to join.

What actually happens in a cardiovascular toxicology evaluation?

The phrase sounds like a laboratory procedure. In practice it is a clinic visit with a handful of ordinary tests attached. ‘Cardiovascular toxicology’ simply means checking whether a medicine or radiation is stressing or damaging the heart and blood vessels, and ‘evaluation’ means the structured way of checking.

The visit usually opens with questions, not machines. A clinician will ask about breathlessness on stairs, swollen ankles, palpitations, fainting and chest discomfort, and about smoking, blood pressure, cholesterol, diabetes and any family history of heart muscle disease. Previous cancer treatment matters too, particularly earlier anthracyclines (a chemotherapy class derived from a soil bacterium that is highly effective and known to affect heart muscle) or radiation to the chest. The answers sort people into broad risk tiers that shape how much testing follows.

Then comes the physical examination: blood pressure, heart sounds, the lung bases, the pulse at the neck, fluid at the ankles. Nothing exotic. A raised blood pressure reading here is one of the most common findings, and one of the most manageable.

The tests themselves are typically done on the same day or within the same week. An electrocardiogram takes a few minutes. An echocardiogram is a longer appointment. Blood is drawn once. Results are read against age- and sex-specific normal ranges and, crucially, are filed as the reference point for every later reading.

The visit ends with a plan rather than a pronouncement: how often to repeat which test, which symptoms should prompt an earlier call, and whether any protective measures are worth discussing with the oncology team. The decision about whether and how cancer treatment proceeds always stays with the treating oncologist, informed by that plan and by the person sitting in the chair.

Which cardio oncology heart tests usually come first?

Three tests do most of the early work, and they are chosen because together they answer three different questions quickly and safely.

The first is the electrocardiogram, or ECG, a recording of the heart’s electrical activity taken through stickers on the chest, arms and legs. It answers: is the rhythm regular, and is the timing of each beat normal? Several cancer drugs can lengthen the QT interval, the time the heart’s lower chambers take to reset electrically, and a baseline ECG is the only way to know whether a later reading has actually changed.

The second is the echocardiogram, an ultrasound scan of the heart. It answers: how strongly is the heart pumping, are the valves working, and is there fluid around the heart? Its headline number is the left ventricular ejection fraction, the percentage of blood the main pumping chamber pushes out with each beat.

The third is blood work, chiefly troponin and a natriuretic peptide. Troponin is a protein released from heart muscle cells when they are injured. Natriuretic peptides (BNP or NT-proBNP) are hormones the heart releases when its walls are stretched or working harder than usual. These answer: is there quiet muscle injury or strain that the scan has not yet caught?

The order is practical rather than sacred. Blood can be drawn at the same appointment as the ECG; the echo may be booked a few days apart. What matters is that all three are recorded before the first dose whenever the treatment schedule allows, because a change is only meaningful against a known starting point.

Cardiac MRI, stress tests and coronary imaging are not first-line. They are reserved for specific questions the basic trio cannot settle, which a later section covers.

Why would a cancer patient need an echocardiogram before chemotherapy?

People with no heart history ask this constantly, and the honest answer is that the scan is looking for what the person cannot feel. A heart can lose a meaningful slice of its pumping strength before anyone notices breathlessness, especially in someone whose activity has already dropped because of cancer or its treatment.

An echocardiogram before chemotherapy does three jobs. It records the baseline ejection fraction so later scans can be compared like-for-like. It picks up pre-existing conditions that change the plan: a stiff or leaking valve, a previously unrecognized weak heart muscle, thickened walls from years of untreated high blood pressure, or fluid in the sac around the heart. And it measures strain, a newer ultrasound technique that tracks how much individual segments of heart muscle shorten with each beat, which can shift before the ejection fraction does.

The test itself is undramatic. You lie on your left side, gel is applied, and a sonographer moves a probe across the chest while grainy images and whooshing sounds appear on screen. According to the NHS, a standard echocardiogram usually takes between 15 minutes and an hour, with no radiation and no recovery time.

Not every chemotherapy regimen triggers a baseline echo. The request is tied to the class of drug rather than to the diagnosis of cancer itself. Anthracyclines, HER2-targeted antibodies used in some breast and stomach cancers, and certain drugs that block blood vessel growth signals are the common prompts. So are immune checkpoint inhibitors, which release the brakes on the immune system and can, uncommonly, cause inflammation of the heart muscle.

If the scan is normal, it is still valuable. A clean baseline is what allows the team to say later, with confidence, that a small change is genuinely new rather than something that was always there.

What does the ECG show, and what does it miss?

The ECG is the oldest test in the set and still one of the most informative for its cost in time. Ten electrodes, a short stretch of lying still, and the machine prints a strip of waves that a trained reader can interpret almost at a glance. The NHS describes the resting version as painless and quick, with no preparation needed beyond removing upper clothing.

What it shows well: heart rate and rhythm, including atrial fibrillation, an irregular and often fast rhythm that some cancer drugs and cancer surgery can provoke; conduction delays, meaning the electrical signal is slow to travel through the heart; evidence of an old heart attack; and the QT interval mentioned earlier. QT prolongation matters because, in rare cases, a very long interval sets the stage for a dangerous rhythm. Oncology drugs that can lengthen it include some tyrosine kinase inhibitors (targeted drugs that block growth signals inside cancer cells), certain anti-nausea medicines and some antibiotics or antifungals used to treat infections during chemotherapy. The baseline ECG lets the team judge whether a later QT is truly longer or was always at the upper end of normal.

What it misses: the ECG says nothing direct about pumping strength. A person can have a normal ECG and a substantially reduced ejection fraction. It also captures only the seconds during which it is recorded, so a rhythm problem that comes and goes may never appear. For that, a wearable monitor worn through ordinary daily life is the usual next step.

Because it is so quick, the ECG tends to be repeated most often, sometimes before every cycle of a QT-affecting drug, while the echocardiogram is spaced out further. Think of the ECG as the pulse check and the echo as the portrait.

What does a troponin test during cancer treatment tell your team?

Troponin is best known from emergency departments, where it helps confirm or exclude a heart attack. In cardio-oncology it plays a subtler role: a sensitive early signal that heart muscle cells are under injury, sometimes before an echocardiogram would register any change in pumping.

The mechanism is straightforward. Troponin proteins live inside heart muscle cells and help the fibers contract. When cells are damaged, the proteins leak into the blood. MedlinePlus notes that levels rise within hours of injury, which is why the test is so useful in acute settings. Modern high-sensitivity assays detect very small amounts, and it is these small rises, rather than the large surges of a heart attack, that cardio-oncology teams watch.

A troponin test during cancer treatment is usually drawn at baseline and then at intervals timed to the drug. A value that stays flat is reassuring. A value that climbs across cycles, even if it remains below any emergency threshold, prompts a closer look: an earlier echocardiogram, a repeat blood test, and a conversation between oncologist and cardiologist about whether protective measures or a change of schedule deserve consideration. That decision sits entirely with the treating team.

The companion test, a natriuretic peptide, answers a different question. BNP and NT-proBNP rise when the heart’s chambers are stretched or working against extra pressure, the pattern seen in heart failure. MedlinePlus describes them as markers used to help diagnose and monitor heart failure. A rising natriuretic peptide with a normal troponin suggests the heart is straining rather than being injured cell by cell, which points the team toward fluid balance and blood pressure.

Neither blood test is perfect. Kidney disease, serious infection, severe anemia and simply being older can push values up without any new heart problem. Interpretation always happens in context, alongside the scan and the symptoms.

Ejection fraction and strain: what the numbers on the echo report mean

Two numbers dominate the cardio-oncology echo report. Both are worth understanding, because they will be read back to you at every follow-up.

Ejection fraction, usually written as LVEF, is the share of blood in the left ventricle that leaves with each beat. It is never 100 percent; a healthy heart keeps a reserve. The American Heart Association gives a normal range of roughly 50 to 70 percent, describes 41 to 49 percent as borderline, and notes that a reading of 40 percent or below may indicate heart failure with reduced pumping. A single reading tells only part of the story. Measurements vary a few points from scan to scan depending on image quality, the person reading it and even how well hydrated you are that morning, so teams look for a sustained change from your own baseline rather than reacting to one number.

Global longitudinal strain, often shortened to GLS, is the average shortening of the heart muscle from base to tip during contraction, expressed as a negative percentage because the muscle gets shorter. It is more sensitive than ejection fraction to early injury: segments of muscle can begin contracting less vigorously while the overall ejection fraction, propped up by the rest of the heart, still looks normal. Guideline groups increasingly treat a meaningful relative fall in strain as an early warning that justifies closer monitoring or a discussion about heart-protective medicines.

What the numbers do not do is dictate the cancer plan on their own. A borderline ejection fraction in someone with no symptoms, good blood pressure and stable strain is a very different situation from the same number with a rising troponin and new breathlessness. Your cardiologist and oncologist weigh the whole picture, and the wording in guidelines is deliberately cautious: ‘consider,’ ‘discuss,’ ‘repeat imaging,’ rather than automatic stop rules.

When are cardiac MRI and other cardiotoxicity screening tests added?

The first-line trio settles most questions. A second tier of cardiotoxicity screening tests is reserved for the cases where it does not.

Cardiac MRI is the usual next step when echocardiogram images are poor, which happens more often than people expect: after breast surgery or radiation, with lung disease, or simply because of body shape, the ultrasound windows can be limited. MRI measures ejection fraction with high precision and, uniquely, can show inflammation, scarring and fluid within the heart muscle itself. That makes it the reference test when immune checkpoint inhibitor myocarditis (inflammation of the heart muscle triggered by the immune system) is suspected. The NHS lists MRI scans as taking anywhere from 15 to 90 minutes, and the test involves lying still inside a tunnel-shaped scanner with no radiation.

Ambulatory rhythm monitoring, a small wearable device that records every heartbeat through normal daily activity, is added when a patient reports palpitations or fainting that a single ECG never captures.

Stress testing, either on a treadmill or with a medicine that mimics exercise while images are taken, comes in when chest pain or breathlessness raises the question of coronary artery narrowing. Some cancer drugs, notably fluoropyrimidines (a chemotherapy class used in bowel and other cancers), can cause coronary spasm, and chest radiation years earlier can accelerate coronary disease. A CT coronary angiogram, a contrast scan of the heart arteries, may be chosen instead.

Home blood pressure monitoring is a quiet but frequent addition, because drugs that block blood vessel growth signals commonly raise blood pressure within the first weeks of treatment.

None of these is routine for everyone. Each is ordered to answer a specific question that the ECG, echo and blood tests have raised, and leaving them out when the basics are normal is not neglect; it is good practice that spares people scans they do not need.

Who is offered cardio oncology heart tests first, and who is usually asked to wait?

Not everyone with cancer needs a cardiology work-up, and the decision is driven by two lists: the treatment and the person.

On the treatment side, baseline testing is generally offered before anthracyclines, HER2-targeted therapy, drugs that block vascular endothelial growth factor (VEGF, the signal that tells blood vessels to grow), some tyrosine kinase inhibitors, immune checkpoint inhibitors, proteasome inhibitors used in myeloma, and radiation fields that include the heart. Certain hormone therapies used in prostate and breast cancer earn attention for their effect on blood pressure, cholesterol and clotting rather than on the pump itself.

On the personal side, priority rises with established heart disease, prior heart failure or heart attack, valve disease, uncontrolled high blood pressure, diabetes, chronic kidney disease, a significant smoking history, older age, and any earlier exposure to anthracyclines or chest radiation. Two or more of these usually move a person into a higher-risk group that receives the full trio before the first dose and closer follow-up afterward.

Who is often asked to wait, or is not referred at all? Someone young, without risk factors, starting a regimen with no recognized heart signal. Someone whose planned treatment is surgery alone. Someone whose oncologist has already obtained a normal ECG and echo recently and has no reason to repeat them. ‘Wait’ here does not mean ignored; it means the oncology team monitors symptoms and blood pressure and refers if anything changes.

There is also a group for whom testing is deliberately paused: people who are acutely unwell, where an urgent cancer treatment cannot reasonably be delayed for a scheduled echo. In that situation the tests are done at the earliest safe opportunity rather than skipped, and the treating team documents the reasoning. The order of priority is always a clinical judgment, made by the people who know the whole case.

How the first-line heart tests compare at a glance

Seeing the tests side by side makes the logic of the sequence clearer. Each one covers a blind spot of the others, which is why they travel together rather than competing.

Test	What it measures	Typical duration (source)	What it cannot show
Electrocardiogram (ECG)	Heart rate, rhythm, electrical timing including the QT interval, signs of past heart attack	A few minutes (NHS)	Pumping strength; rhythm problems that are not present during the recording
Echocardiogram	Ejection fraction, strain, valve function, wall thickness, fluid around the heart	15 minutes to 1 hour (NHS)	Inflammation or scarring inside the muscle; coronary artery narrowing
Troponin blood test	Leak of protein from injured heart muscle cells	Single blood draw	Why the cells are injured; strain without cell damage
Natriuretic peptide (BNP or NT-proBNP)	Stretch and pressure load on the heart chambers	Single blood draw	Cell injury; the cause of the strain
Cardiac MRI (second line)	Precise ejection fraction, inflammation, scarring, tissue character	15 to 90 minutes (NHS)	Rhythm over time; less accessible and not suitable for some implanted devices

Two details are easy to miss in a table. The ECG and the blood tests are cheap in time and can be repeated often, so they act as the early tripwires. The echocardiogram is slower and more operator-dependent, so it is the anchor for confirming a change rather than the first alarm. Cardiac MRI is the tiebreaker: precise, detailed and reserved for the moments when the anchor itself is in doubt.

The pattern also explains a frustration many patients voice: why they were sent for blood work twice before anyone repeated the scan. The answer is not oversight. It is that the blood tests are meant to move first.

What the following weeks usually look like once treatment starts

Once the baseline is filed, the rhythm of monitoring depends on the drug and the risk tier, and it is set by the treating team rather than by a fixed calendar. Some patterns are common enough to describe.

For regimens that affect rhythm, the ECG is often repeated shortly after starting and then at intervals, sometimes before dose adjustments, because QT changes tend to appear early. For regimens that raise blood pressure, home readings in the first weeks are the most useful data anyone will collect, and a modest rise handled promptly rarely derails treatment.

For regimens that affect pumping strength, echocardiograms are typically spaced through treatment and repeated at the end, with an additional scan whenever symptoms, troponin or strain suggest a change. Blood tests are often drawn with routine oncology labs, which spares an extra needle.

What a change looks like in practice: a phone call to bring the next scan forward, a same-week visit, sometimes a decision by the oncologist to delay a cycle while the cardiologist starts or adjusts a heart-protective medicine. Beta blockers and drugs acting on the renin-angiotensin system (a hormone pathway that controls blood pressure and fluid) are the classes most often discussed because they reduce the workload on a stressed heart. Whether they are appropriate, and when, is a decision for the prescribing clinician.

After treatment ends, surveillance continues for those with higher exposure, because anthracycline-related weakening can surface years later and chest radiation effects can take many years to appear. A survivorship plan should say which tests are repeated and how often.

The emotional side deserves a sentence. Serial testing can feel like waiting for bad news. Most repeat scans are unchanged, and a stable set of numbers is exactly what the process is designed to document.

Which cancer treatments are linked to heart effects, and how?

The heart is not a random bystander. Each treatment class has its own mechanism, and knowing the mechanism explains which test is watching for it.

Anthracyclines damage heart muscle cells directly, partly by generating reactive oxygen molecules that injure the cell’s energy factories and partly by interfering with an enzyme heart cells use to maintain their DNA. The effect accumulates with total lifetime exposure and can be long-lasting, which is why echocardiography and troponin are watched through and after treatment.

HER2-targeted antibodies block a growth signal that cancer cells over-use, but healthy heart cells also rely on the same signal to cope with stress. The result is a weakening of the pump that, in many people, improves when the drug is paused and heart-protective treatment is given. The echocardiogram is the key test here.

VEGF inhibitors and related tyrosine kinase inhibitors stop blood vessels growing, which starves tumors but also stiffens and constricts normal vessels. Raised blood pressure is the earliest and most common signal, followed occasionally by protein in the urine, clots or a weakened pump. Home blood pressure checks and the echo cover this ground.

Immune checkpoint inhibitors can cause the immune system to attack heart muscle, producing myocarditis. It is uncommon but tends to appear early and can be severe, so troponin and ECG changes, with cardiac MRI to confirm, are the watchwords.

Fluoropyrimidines can trigger spasm of the coronary arteries, causing chest pain that mimics a heart attack, usually during or soon after an infusion. The ECG and troponin catch it.

Radiation to the chest scars the pericardium, valves, coronary arteries and muscle slowly, over many years, which is why long-term survivors are offered periodic echocardiography.

Hormone therapies used in prostate and breast cancer act on cholesterol, blood sugar, weight and clotting, shifting cardiovascular risk indirectly and making blood pressure and lipid checks the relevant tests.

What people often get wrong about heart tests during cancer care

Myths gather quickly around any test that arrives unannounced. A few deserve to be cleared away.

The first is that a cardio-oncology referral means the heart is already damaged. It almost never does. Baseline testing is booked because of the planned drug, not because of a finding. Most people referred before treatment have normal results and are simply being measured before the exposure.

The second is that a normal baseline echo means the heart is ‘cleared’ for good. A normal scan is a starting line, not a finish line. The whole point of recording it is to compare later scans against it, and some effects emerge only after several cycles or well after treatment ends.

The third is the search phrase ‘first symptoms of heart cancer.’ Cancer that begins in the heart itself is extraordinarily rare; most tumors found in the heart have spread there from elsewhere, and even that is uncommon. When a person with cancer develops heart symptoms, the cause is almost always treatment-related, pre-existing heart disease or something unrelated such as anemia or infection. Anyone worried about new symptoms should ask a clinician rather than measure themselves against a checklist.

The fourth is that starting a heart-protective medicine means the cancer drug is unsafe. In practice the two are complementary. Supporting the heart is often what allows a proven cancer treatment to continue at full strength.

The fifth is that a raised troponin equals a heart attack. In cardio-oncology, small rises usually signal low-grade muscle stress, and the team responds with closer monitoring rather than emergency procedures.

The last is that one low ejection fraction reading ends treatment. Guidelines favor repeat imaging, review of strain and symptoms, and a joint decision. Numbers inform the plan; they do not write it.

Questions to ask your care team before and during monitoring

The most useful questions are the ones that tell you how your own plan works, rather than how cardio-oncology works in general. Bring these to the first visit, and revisit them when results come back.

• Which of my planned treatments prompted this heart evaluation, and what specific effect are you watching for?
• What are my baseline ejection fraction and strain values, and what kind of change would you consider meaningful for me?
• How often will the ECG, echocardiogram and blood tests be repeated, and will the blood tests be drawn with my routine oncology labs?
• Do you want me to check my blood pressure at home, and if so, what reading should prompt a call?
• Are there symptoms you would like to hear about the same day, rather than at the next appointment?
• If a result changes, who makes the decision about my cancer treatment, and how will the cardiology and oncology teams communicate with each other and with me?
• Are heart-protective medicines something you are considering for me now, and what would the reasoning be either way?
• After treatment ends, which heart tests will continue, for how long, and who will arrange them?

Two more are worth asking even if they feel awkward. First: ‘Is there anything in my history, such as earlier chemotherapy or radiation, that you need records of?’ Old treatment summaries change risk tiers and are often missing from current files. Second: ‘What can I do in the meantime?’ Blood pressure control, not smoking, moving daily and keeping diabetes well managed are the ordinary levers that reduce cardiovascular risk for anyone, and they remain in your hands during cancer treatment.

Write the answers down, or ask for them in the after-visit summary. The value of a baseline is that it can be compared later, and that is true of conversations as well as scans.

When to call your doctor

Scheduled tests catch slow changes. Some changes are not slow, and the monitoring plan only works if people know which symptoms should jump the queue.

Call emergency services, or go to the nearest emergency department, for chest pain or pressure that lasts more than a few minutes or comes with sweating, nausea or pain spreading to the arm, neck or jaw; for sudden severe breathlessness; for fainting or near-fainting; or for a very fast or pounding heartbeat accompanied by dizziness or chest discomfort. During an infusion, tell the nursing staff immediately about any chest tightness.

Call your oncology or cardiology team the same day, rather than waiting for the next appointment, for new breathlessness on exertion that was not there last week, breathlessness when lying flat or waking you at night, new swelling of the ankles, legs or abdomen, rapid unexplained weight gain over a few days, palpitations that come and go, home blood pressure readings that are consistently much higher than your usual, especially with headache or visual disturbance, or new pain and swelling in one leg, which can signal a clot.

Fever during chemotherapy is a separate emergency with its own pathway and should always be reported at once.

Do not stop, skip or change any medicine, including a heart medicine, on the basis of a symptom or a home reading without speaking to the prescribing clinician. Equally, do not wait for a scheduled scan to mention something that worries you. Bringing a test forward is a routine, low-drama event in cardio-oncology, and teams would far rather perform an extra echocardiogram that turns out normal than hear about breathlessness three weeks late.

Every decision about your treatment, heart or cancer, sits with the team that knows your full picture. Your job is to give them the information early.

Frequently asked questions

What is cardio-oncology?

Cardio-oncology is the specialty that protects the heart and blood vessels of people before, during and after cancer treatment. It brings cardiologists and oncologists together to assess risk, take baseline heart measurements, monitor for changes caused by chemotherapy, targeted drugs, immunotherapy or radiation, and manage any problems so that effective cancer treatment can continue wherever possible. It covers long-term survivors as well as people currently in treatment.

Why would a cancer patient need an echocardiogram before chemotherapy?

A baseline echocardiogram records how strongly the heart pumps before any exposure, so later scans can be compared accurately. It also detects pre-existing valve disease, thickened walls or a quietly weak heart that would change how treatment is planned. The request is tied to the drug class, such as anthracyclines or HER2-targeted therapy, rather than to the cancer itself, and a normal result is valuable because it defines what ‘unchanged’ will mean later.

Is it serious to be referred to an oncologist?

A referral to an oncologist means a specialist is being asked to confirm, stage or plan treatment for a suspected or diagnosed cancer; it does not in itself say how advanced the condition is or what the outlook will be. Many referrals lead to early-stage findings or to conditions that are managed for years. The referral is the standard route to specialist care, and the oncologist will explain what the tests show and what the options are.

What are the first symptoms of heart cancer?

Cancer that starts in the heart is extraordinarily rare, and most tumors found in the heart have spread from elsewhere. Because it is so uncommon, no reliable list of early symptoms exists, and heart-related symptoms in people with cancer are far more often due to treatment effects, existing heart disease, anemia or infection. Anyone with new breathlessness, chest discomfort, palpitations or swelling should describe them to a clinician rather than try to match them to a diagnosis.

What does a troponin test during cancer treatment show?

Troponin is a protein that leaks from heart muscle cells when they are injured, and MedlinePlus notes that levels rise within hours of damage. During cancer treatment it is measured at baseline and at intervals; a value that stays flat is reassuring, while a steady climb across cycles, even below emergency thresholds, prompts an earlier echocardiogram and a joint review. Kidney disease, infection and anemia can also raise it, so results are always read in context.

How often are cardiotoxicity screening tests repeated?

The schedule is set by the treating team according to the drug class and the person’s risk tier, not by a universal calendar. ECGs and blood tests are quick and tend to be repeated most often, sometimes before cycles of rhythm-affecting drugs. Echocardiograms are spaced through treatment and repeated at the end, with extra scans if symptoms or blood results change. People with higher exposure, especially to anthracyclines or chest radiation, continue periodic checks after treatment finishes.

Is a cardiac MRI better than an echocardiogram for cancer patients?

Cardiac MRI is more precise for ejection fraction and can show inflammation and scarring inside the muscle, but it is slower, less available and unsuitable for some implanted devices, so it is used as a second-line test rather than a replacement. Echocardiography remains the first-line scan because it is quick, radiation-free and easily repeated. MRI is typically added when echo images are poor or when myocarditis from immune checkpoint inhibitors is suspected.

What ejection fraction is normal on an echocardiogram?

The American Heart Association describes a normal left ventricular ejection fraction as roughly 50 to 70 percent, a range of 41 to 49 percent as borderline, and 40 percent or below as possibly indicating heart failure with reduced pumping. Readings vary a few points between scans, so cardio-oncology teams focus on a sustained change from your own baseline, considered alongside strain measurements, blood tests and symptoms, rather than on any single number.

Can heart changes from cancer treatment improve?

It depends on the mechanism. Weakening linked to HER2-targeted therapy often improves when the drug is paused and heart-protective treatment is given, whereas anthracycline-related damage can be longer-lasting, which is why it is monitored so closely. Early detection through troponin, strain and ejection fraction gives the team the widest range of options. No outcome can be promised, and decisions about pausing or continuing cancer treatment always rest with the treating oncologist and cardiologist together.

Do I need heart tests after my cancer treatment ends?

Many people do, particularly after anthracyclines, chest radiation or a documented change during treatment, because some effects appear years later. A survivorship plan should state which tests continue, typically periodic echocardiography and blood pressure checks, and who arranges them. People with no exposure to heart-affecting treatments and normal results throughout may need no specific cardiac follow-up beyond ordinary cardiovascular risk management, which your oncology team can confirm.

References

• MedlinePlus: Troponin Test
• MedlinePlus: Natriuretic Peptide Tests (BNP, NT-proBNP)
• NHS: Echocardiogram
• NHS: Electrocardiogram (ECG)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.